# A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers

> **NCT06637865** · PHASE1 · RECRUITING · sponsor: **Immutep S.A.S.** · enrollment: 79 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** IMP761
- **DRUG:** Placebo
- **OTHER:** keyhole limpet haemocyanin (KLH)

## Key facts

- **NCT ID:** NCT06637865
- **Lead sponsor:** Immutep S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-17
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 79 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06637865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06637865, "A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06637865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*